Christina Glover, MD
Endocrinology, Diabetes & Metabolism · Jackson, MSNPI 1356638845
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 369 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 13.4% — the pattern of someone who eats at a lot of different presentations.
Across 369 payments — averaging $19.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$942
- Novo Nordisk$619
- Amgen$577
- Corcept Therapeutics$558
- Boehringer Ingelheim$529
- AstraZeneca$451
- plus $3K from 34 others
What the payments were for
- Food & beverage$7,040100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 61 | $942 |
| Novo Nordisk | 31 | $619 |
| Amgen | 35 | $577 |
| Corcept Therapeutics | 17 | $558 |
| Boehringer Ingelheim | 31 | $529 |
| AstraZeneca(2 entities) | 25 | $451 |
| Abbott | 23 | $421 |
| Novartis | 14 | $279 |
| Dexcom, Inc. | 10 | $238 |
| Sanofi-aventis U.S. LLC | 14 | $230 |
| AbbVie | 13 | $204 |
| Valeritas, Inc. | 11 | $173 |
| Bayer | 3 | $166 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $158 |
| Cequr Corporation | 1 | $139 |
| BETA Bionics, Inc. | 7 | $129 |
| Insulet Corporation | 6 | $129 |
| Pfizer | 7 | $127 |
| Radius Health, Inc. | 7 | $121 |
| Eisai Inc. | 1 | $102 |
| Tandem Diabetes Care, Inc. | 4 | $80 |
| Ultragenyx Pharmaceutical Inc. | 5 | $78 |
| Amryt Pharma Holdings Ltd | 3 | $75 |
| Medtronic | 4 | $74 |
| Merck | 5 | $71 |
| Regeneron Healthcare Solutions, Inc. | 3 | $46 |
| Kyowa Kirin, Inc. | 2 | $40 |
| Sequel Med Tech, LLC | 2 | $36 |
| Averitas Pharma Inc. | 1 | $29 |
| Shire North American Group Inc | 2 | $29 |
| Madrigal Pharmaceuticals | 1 | $25 |
| Johnson & Johnson | 2 | $22 |
| Ascensia Diabetes Care US Inc. | 1 | $22 |
| Recordati_rare_diseases_inc. | 1 | $21 |
| Chiesi USA, Inc. | 1 | $21 |
| Rhythm Pharmaceuticals, Inc. | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Ascendis Pharma Endocrinology Inc | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| IBSA Pharma Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$140
- CeQur Simplicity$139
- Kerendia$125
- Wegovy$119
- LENVIMA$102
How this compares
$7,049 in reported general payments places this provider in the 55th percentile of 48 endocrinology, diabetes & metabolism providers in Mississippi.
See all endocrinology, diabetes & metabolism providers in Mississippi →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 431 | $584,269 |
| JardianceEmpagliflozin | 195 | $227,641 |
| Tresiba Flextouch U-200Insulin Degludec | 136 | $165,005 |
| MounjaroTirzepatide | 122 | $139,550 |
| TrulicityDulaglutide | 100 | $105,462 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 87 | $100,333 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 71 | $96,021 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 27 | $63,326 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 47 | $61,534 |
| FarxigaDapagliflozin Propanediol | 43 | $54,977 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 54 | $42,938 |
| Novolog FlexpenInsulin Aspart | 153 | $38,530 |
| ProliaDenosumab | 21 | $34,932 |
| JanuviaSitagliptin Phosphate | 28 | $29,983 |
| Tresiba Flextouch U-100Insulin Degludec | 68 | $29,456 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus, Novolog | $619 | $671,976529 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $529 | $271,760235 claims |
| Lilly USA, LLCMounjaro, Trulicity, Baqsimi, Humalog | $942 | $258,025258 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $230 | $96,02171 claims |
| AstraZenecaFarxiga | $451 | $54,97743 claims |
| AmgenProlia | $577 | $34,93221 claims |
| MerckJanuvia | $71 | $29,98328 claims |
| AbbVieSynthroid | $204 | $6,06756 claims |
| PfizerLyrica | $127 | $3,72411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 48 endocrinology, diabetes & metabolism providers in Mississippi.
Other endocrinology, diabetes & metabolism in Jackson
- Eric DyessJackson$885K
- Honey EastJackson$721K
- Ben SealeJackson$623K
- Amanda SchieferJackson$204K
- John SistrunkJackson$41K
- Raymond GrenfellJackson$16K
- Vanessa SandiferJackson$14K
- John KnightJackson$9K
- Jana PhillipsJackson$8K
- Robert EvansJackson$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.